Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
RAPT Therapeutics $75 million follow-on offering
The shares are listed on the Nasdaq Global Market
TMS ¥2.9 billion global IPO
The shares are listed on the Tokyo Stock Exchange
Brookdale Senior Living $125 million tangible equity units offering
The offering comprised 2.5 million units
Privia Health $135 million secondary offering
We advised Privia on its debut shelf takedown offering
Tenaya Therapeutics $75 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Natera $400 million follow-on offering
The shares are listed on Nasdaq
Zoetis $1.35 billion senior notes offering
The investment-grade notes are due 2025 and 2032
Metalmark Capital up to $50 million investment in Morgenesis
We advised Metalmark on the transaction
Roivant Sciences $150 million equity offering
We advised the company on its debut SEC-registered primary and secondary offering
Akoya Biosciences $50 million at-the-market program
The common stock is listed on the Nasdaq Global Select Market